Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.
Identifieur interne : 000522 ( PubMed/Corpus ); précédent : 000521; suivant : 000523Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.
Auteurs : Margaret Lartey ; Kwamena W. Sagoe ; Hongmei Yang ; Ernest Kenu ; Fafa Xexemeku ; Joseph Oliver-Commey ; Vincent Boima ; Markafui Seshie ; Augustine Sagoe ; Julius A A. Mingle ; Timothy P. Flanigan ; Hulin Wu ; Awewura KwaraSource :
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [ 1537-6591 ] ; 2011.
English descriptors
- KwdEn :
- Adult, Anti-HIV Agents (administration & dosage), Antiretroviral Therapy, Highly Active (methods), Antitubercular Agents (administration & dosage), Benzoxazines (administration & dosage), Female, HIV (isolation & purification), HIV Infections (complications), HIV Infections (drug therapy), HIV Infections (virology), Humans, Male, Tuberculosis (complications), Viral Load, Viremia.
- MESH :
- chemical , administration & dosage : Anti-HIV Agents, Antitubercular Agents, Benzoxazines.
- complications : HIV Infections, Tuberculosis.
- drug therapy : HIV Infections.
- isolation & purification : HIV.
- methods : Antiretroviral Therapy, Highly Active.
- virology : HIV Infections.
- Adult, Female, Humans, Male, Viral Load, Viremia.
Abstract
Viral decay rates during efavirenz-based therapy were compared between human immunodeficiency virus (HIV)-infected patients without tuberculosis (n = 40) and those with tuberculosis coinfection who were receiving concurrent antituberculous therapy (n = 34). Phase I and II viral decay rates were similar in the 2 groups (P > .05). Overall, concurrent antituberculous therapy did not reduce the efficacy of the HIV treatment.
DOI: 10.1093/cid/ciq196
PubMed: 21252140
Links to Exploration step
pubmed:21252140Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.</title><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name><affiliation><nlm:affiliation>University of Ghana Medical School, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Sagoe, Kwamena W" sort="Sagoe, Kwamena W" uniqKey="Sagoe K" first="Kwamena W" last="Sagoe">Kwamena W. Sagoe</name></author><author><name sortKey="Yang, Hongmei" sort="Yang, Hongmei" uniqKey="Yang H" first="Hongmei" last="Yang">Hongmei Yang</name></author><author><name sortKey="Kenu, Ernest" sort="Kenu, Ernest" uniqKey="Kenu E" first="Ernest" last="Kenu">Ernest Kenu</name></author><author><name sortKey="Xexemeku, Fafa" sort="Xexemeku, Fafa" uniqKey="Xexemeku F" first="Fafa" last="Xexemeku">Fafa Xexemeku</name></author><author><name sortKey="Oliver Commey, Joseph" sort="Oliver Commey, Joseph" uniqKey="Oliver Commey J" first="Joseph" last="Oliver-Commey">Joseph Oliver-Commey</name></author><author><name sortKey="Boima, Vincent" sort="Boima, Vincent" uniqKey="Boima V" first="Vincent" last="Boima">Vincent Boima</name></author><author><name sortKey="Seshie, Markafui" sort="Seshie, Markafui" uniqKey="Seshie M" first="Markafui" last="Seshie">Markafui Seshie</name></author><author><name sortKey="Sagoe, Augustine" sort="Sagoe, Augustine" uniqKey="Sagoe A" first="Augustine" last="Sagoe">Augustine Sagoe</name></author><author><name sortKey="Mingle, Julius A A" sort="Mingle, Julius A A" uniqKey="Mingle J" first="Julius A A" last="Mingle">Julius A A. Mingle</name></author><author><name sortKey="Flanigan, Timothy P" sort="Flanigan, Timothy P" uniqKey="Flanigan T" first="Timothy P" last="Flanigan">Timothy P. Flanigan</name></author><author><name sortKey="Wu, Hulin" sort="Wu, Hulin" uniqKey="Wu H" first="Hulin" last="Wu">Hulin Wu</name></author><author><name sortKey="Kwara, Awewura" sort="Kwara, Awewura" uniqKey="Kwara A" first="Awewura" last="Kwara">Awewura Kwara</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21252140</idno><idno type="pmid">21252140</idno><idno type="doi">10.1093/cid/ciq196</idno><idno type="wicri:Area/PubMed/Corpus">000522</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000522</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.</title><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name><affiliation><nlm:affiliation>University of Ghana Medical School, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Sagoe, Kwamena W" sort="Sagoe, Kwamena W" uniqKey="Sagoe K" first="Kwamena W" last="Sagoe">Kwamena W. Sagoe</name></author><author><name sortKey="Yang, Hongmei" sort="Yang, Hongmei" uniqKey="Yang H" first="Hongmei" last="Yang">Hongmei Yang</name></author><author><name sortKey="Kenu, Ernest" sort="Kenu, Ernest" uniqKey="Kenu E" first="Ernest" last="Kenu">Ernest Kenu</name></author><author><name sortKey="Xexemeku, Fafa" sort="Xexemeku, Fafa" uniqKey="Xexemeku F" first="Fafa" last="Xexemeku">Fafa Xexemeku</name></author><author><name sortKey="Oliver Commey, Joseph" sort="Oliver Commey, Joseph" uniqKey="Oliver Commey J" first="Joseph" last="Oliver-Commey">Joseph Oliver-Commey</name></author><author><name sortKey="Boima, Vincent" sort="Boima, Vincent" uniqKey="Boima V" first="Vincent" last="Boima">Vincent Boima</name></author><author><name sortKey="Seshie, Markafui" sort="Seshie, Markafui" uniqKey="Seshie M" first="Markafui" last="Seshie">Markafui Seshie</name></author><author><name sortKey="Sagoe, Augustine" sort="Sagoe, Augustine" uniqKey="Sagoe A" first="Augustine" last="Sagoe">Augustine Sagoe</name></author><author><name sortKey="Mingle, Julius A A" sort="Mingle, Julius A A" uniqKey="Mingle J" first="Julius A A" last="Mingle">Julius A A. Mingle</name></author><author><name sortKey="Flanigan, Timothy P" sort="Flanigan, Timothy P" uniqKey="Flanigan T" first="Timothy P" last="Flanigan">Timothy P. Flanigan</name></author><author><name sortKey="Wu, Hulin" sort="Wu, Hulin" uniqKey="Wu H" first="Hulin" last="Wu">Hulin Wu</name></author><author><name sortKey="Kwara, Awewura" sort="Kwara, Awewura" uniqKey="Kwara A" first="Awewura" last="Kwara">Awewura Kwara</name></author></analytic><series><title level="j">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</title><idno type="eISSN">1537-6591</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Anti-HIV Agents (administration & dosage)</term><term>Antiretroviral Therapy, Highly Active (methods)</term><term>Antitubercular Agents (administration & dosage)</term><term>Benzoxazines (administration & dosage)</term><term>Female</term><term>HIV (isolation & purification)</term><term>HIV Infections (complications)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (virology)</term><term>Humans</term><term>Male</term><term>Tuberculosis (complications)</term><term>Viral Load</term><term>Viremia</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term><term>Antitubercular Agents</term><term>Benzoxazines</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term><term>Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>HIV</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Antiretroviral Therapy, Highly Active</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Female</term><term>Humans</term><term>Male</term><term>Viral Load</term><term>Viremia</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Viral decay rates during efavirenz-based therapy were compared between human immunodeficiency virus (HIV)-infected patients without tuberculosis (n = 40) and those with tuberculosis coinfection who were receiving concurrent antituberculous therapy (n = 34). Phase I and II viral decay rates were similar in the 2 groups (P > .05). Overall, concurrent antituberculous therapy did not reduce the efficacy of the HIV treatment.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21252140</PMID><DateCreated><Year>2011</Year><Month>01</Month><Day>24</Day></DateCreated><DateCompleted><Year>2011</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.</ArticleTitle><Pagination><MedlinePgn>547-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciq196</ELocationID><Abstract><AbstractText>Viral decay rates during efavirenz-based therapy were compared between human immunodeficiency virus (HIV)-infected patients without tuberculosis (n = 40) and those with tuberculosis coinfection who were receiving concurrent antituberculous therapy (n = 34). Phase I and II viral decay rates were similar in the 2 groups (P > .05). Overall, concurrent antituberculous therapy did not reduce the efficacy of the HIV treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lartey</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Ghana Medical School, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagoe</LastName><ForeName>Kwamena W</ForeName><Initials>KW</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hongmei</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kenu</LastName><ForeName>Ernest</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Xexemeku</LastName><ForeName>Fafa</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Oliver-Commey</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Boima</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Seshie</LastName><ForeName>Markafui</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sagoe</LastName><ForeName>Augustine</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mingle</LastName><ForeName>Julius A A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Flanigan</LastName><ForeName>Timothy P</ForeName><Initials>TP</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hulin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kwara</LastName><ForeName>Awewura</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 DA013868</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AI078498</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30DA013868</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI071760</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>9P30 AI50410</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AI078498</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AI050410</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048588">Benzoxazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>JE6H2O27P8</RegistryNumber><NameOfSubstance UI="C098320">efavirenz</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Aug 24;23(13):1717-25</RefSource><PMID Version="1">19461502</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2006 Aug 1;20(12):1605-12</RefSource><PMID Version="1">16868441</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2006 Dec;58(6):1299-302</RefSource><PMID Version="1">17032686</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2001 Nov 24;358(9295):1760-5</RefSource><PMID Version="1">11734232</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1995 Jan 12;373(6510):123-6</RefSource><PMID Version="1">7816094</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1998 Jul 30;12(11):F111-5</RefSource><PMID Version="1">9708400</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biometrics. 1999 Jun;55(2):410-8</RefSource><PMID Version="1">11318194</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1999 Apr;179(4):799-807</RefSource><PMID Version="1">10068574</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2003 Jun 15;187(12):1967-71</RefSource><PMID Version="1">12792875</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):439-43</RefSource><PMID Version="1">19223781</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2003 Dec 5;17(18):2615-22</RefSource><PMID Version="1">14685055</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2005 Feb;75(2):202-8</RefSource><PMID Version="1">15602734</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biostatistics. 2001 Mar;2(1):13-29</RefSource><PMID Version="1">12933554</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1999 Feb 25;13(3):429-30</RefSource><PMID Version="1">10199240</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Chest Med. 2005 Jun;26(2):283-94, vi-vii</RefSource><PMID Version="1">15837111</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2004 Nov 1;190(9):1670-6</RefSource><PMID Version="1">15478074</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2003 Mar 15;187(6):896-900</RefSource><PMID Version="1">12660935</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):148-52</RefSource><PMID Version="1">19131895</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2006 May 15;193(10):1437-40</RefSource><PMID Version="1">16619192</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2006 Sep;43(1):42-6</RefSource><PMID Version="1">16885778</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Feb 25;362(8):697-706</RefSource><PMID Version="1">20181971</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2004 Feb 15;189(4):593-601</RefSource><PMID Version="1">14767811</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Clin Pharmacol. 2009 Apr;67(4):427-36</RefSource><PMID Version="1">19371316</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ther Drug Monit. 2006 Aug;28(4):517-25</RefSource><PMID Version="1">16885719</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2007 Apr 15;195(8):1169-76</RefSource><PMID Version="1">17357053</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023241" MajorTopicYN="N">Antiretroviral Therapy, Highly Active</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048588" MajorTopicYN="N">Benzoxazines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006678" MajorTopicYN="N">HIV</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="N">Tuberculosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="Y">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014766" MajorTopicYN="Y">Viremia</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC3060905</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21252140</ArticleId><ArticleId IdType="pii">ciq196</ArticleId><ArticleId IdType="doi">10.1093/cid/ciq196</ArticleId><ArticleId IdType="pmc">PMC3060905</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000522 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000522 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21252140
|texte= Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21252140" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |